Panion reports successful safety study in dogs

Panion Animal Health AB develops a unique new gene therapy treatment for dogs with epilepsy. In spring 2018, a safety study in dogs was started under the lead of Associate Professor David Woldbye, Department of Neuroscience, University of Copenhagen. The clinical phase of the study is now finalised, and the first preliminary outcome can be reported.

All treated dogs have successfully completed the study without observable adverse reactions. Neurological examination of the dogs before and after the treatment showed no related changes, and the dogs exhibited ordinary behavior shortly after the gene therapy treatment procedure.

"We are extremely satisfied with the conduct and clinical results of the study. The observations confirm the good results that we have seen in earlier preclinical studies in 
rats and dogs." says CEO Anja Holm, "The many laboratory tests and samples will now be handled and analysed, and we expect that they support the direct observations. When a detailed report is ready in a couple of months, we will inform the market again."

The positive results from the safety study paves the way for conducting clinical trials in privately owned dogs that suffer from drug-refractory epilepsy. 1-2 % of all dogs worldwide have epilepsy and a third of these are not well controlled with medication. Panion's new gene therapy product is intended to cover the therapeutic gap for such dogs and their caring owners.

This press release contains information which Panion Animal Health AB is obliged to publish according to the EU market abuse regulation (MAR). This information was submitted by Panion's CEO, Anja E. H. Holm, for publication on August 30 2018.

2018-08-30

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com 

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Nerladdningsbara filer

Panion attracts attention from animal health media

Panion is attracting interest from the agribusiness intelligence and animal health media Animal Pharm, where journalist Sian Lazell yesterday, 31.st of January 2019, noted the news on financing of the development program from Panion: https://bit.ly/2t1tgeK "Panion secures extra funding to back R&D. The financing round was carried out through the issuance of notes with warrants attached to Yorkville Advisors Global, that have a principal amount of SEK 100,000 each.


Panion kallar på en andra tranche av konvertibler om 2 miljoner kronor

Panion Animal Health AB ("Panion") kallar på en andra tranche från den investeringsfond som förvaltas av Yorkville Advisors Global ("Yorkville").


Panion draws down a second tranche of convertibles of SEK 2 million

Panion Animal Health AB ("Panion") draws down a second tranche from the investment fund managed by Yorkville Advisors Global ("Yorkville").  




The rights issue in Panion Animal Health AB has been registered by the Swedish Companies Registration Office

The rights issue which was decided by the Board of Panion Animal Health AB, with the authorization of the Annual General Meeting of 29 May 2018, has now been registered by the Swedish Companies Registration Office. Shares and share capital after the registration by the Swedish Companies Registration Office amount to SEK 1,137,110.723254 divided into 24,399,487 shares.







Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: